Literature DB >> 7562440

Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion.

Y Wang1, R J Sawchuk.   

Abstract

The distribution of zidovudine (AZT) between plasma, brain extracellular fluid (ECF), and cerebrospinal fluid (CSF) was investigated in a crossover design study (n = 5) in unanesthetized rabbits. Drug was administered by intravenous (iv) and intracerebroventricular (icv) infusions at the same infusion rate (1.5 mg/h.kg). The concentrations of AZT in ECF and CSF were measured by HPLC with microdialysis sampling. Plasma concentrations of AZT were quantitated by HPLC. Following iv infusion, the ECF- and CSF-to-plasma concentration ratios at steady state (SS), were 0.19 +/- 0.05 and 0.29 +/- 0.06, respectively. These values were less than unity, indicating the existence of active transport processes for the transport of AZT from brain to plasma across the blood-brain barrier (BBB) or blood-CSF barrier (BCB). The transport processes were modeled by compartmental model analysis, and the results suggest that the transport efficiency of AZT across the BBB is asymmetric; that is, the efflux clearance was five times greater than the influx clearance. Similarly, the efflux clearance from CSF is three times larger than the influx clearance into CSF. The SS concentrations of AZT in brain ECF in the same animals that received an icv infusion of AZT in the crossover design study were approximately two orders of magnitude greater than those in animals following iv infusion at the same dosing rate. Nevertheless, the SS plasma concentrations of AZT were similar for both routes of administration (1.2 +/- 0.19 and 1.2 +/- 0.13 micrograms/mL for iv and icv routes, respectively), confirming that the brain is not an organ that exhibits first-pass metabolism under the present experimental conditions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562440     DOI: 10.1002/jps.2600840717

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  18 in total

Review 1.  The impact of efflux transporters in the brain on the development of drugs for CNS disorders.

Authors:  Eve M Taylor
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats.

Authors:  Jeffrey E Edwards; Kenneth R Brouwer; Patrick J McNamara
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 3.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.

Authors:  Markus Müller; Amparo dela Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 4.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

Review 5.  Targeting anti-HIV drugs to the CNS.

Authors:  Kavitha S Rao; Anuja Ghorpade; Vinod Labhasetwar
Journal:  Expert Opin Drug Deliv       Date:  2009-08       Impact factor: 6.648

6.  Overview of microdialysis.

Authors:  T S Shippenberg; A C Thompson
Journal:  Curr Protoc Neurosci       Date:  2001-05

7.  Drug equilibration across the blood-brain barrier--pharmacokinetic considerations based on the microdialysis method.

Authors:  M Hammarlund-Udenaes; L K Paalzow; E C de Lange
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

Review 8.  Application of microdialysis in pharmacokinetic studies.

Authors:  W F Elmquist; R J Sawchuk
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

9.  The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach.

Authors:  Y Wang; D F Welty
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

Review 10.  CSF penetration by antiretroviral drugs.

Authors:  Christine Eisfeld; Doris Reichelt; Stefan Evers; Ingo Husstedt
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.